Brief: Yumanity Therapeutics’ YTX-7739 Achieved Target Engagement At Doses That Were Generally Well Tolerated In A Phase 1A Multiple Ascending Dose Study In Healthy Volunteers

Kineta

22/04/2021 12:46

April 22 (Reuters) - Yumanity Therapeutics Inc  YMTX.O :
    * YUMANITY THERAPEUTICS’ YTX-7739 ACHIEVED TARGET ENGAGEMENT
AT
DOSES THAT WERE GENERALLY WELL TOLERATED IN A PHASE 1A MULTIPLE
ASCENDING DOSE STUDY IN HEALTHY VOLUNTEERS
    * YUMANITY THERAPEUTICS - INHIBITION OF STEAROYL-COA
DESATURASE
SHOWN TO IMPROVE MOTOR FUNCTION & OTHER DISEASE MARKERS IN
TRANSGENIC MOUSE MODELS OF PD
    * YUMANITY THERAPEUTICS INC - YTX-7739 WAS ALSO OBSERVED TO
BE
GENERALLY WELL TOLERATED IN PHASE 1A STUDY
    * YUMANITY THERAPEUTICS INC - TOPLINE RESULTS FROM PHASE 1B
PART
OF STUDY ARE EXPECTED IN MID-2021

Source text for Eikon:  ID:nGNX6CGcR1 
Further company coverage:  YMTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))